482 related articles for article (PubMed ID: 26408304)
41. Rationale and study design of the IRENE-trial (NVALT-16): a phase II trial to evaluate iressa rechallenge in advanced NSCLC patients with an activating EGFR mutation who responded to an EGFR-TKI used as first-line or previous treatment.
Kuiper JL; Heideman DA; Würdinger T; Grünberg K; Groen HJ; Smit EF
Clin Lung Cancer; 2015 Jan; 16(1):60-6. PubMed ID: 25242669
[TBL] [Abstract][Full Text] [Related]
42. Treatment of ALK-positive non-small cell lung cancer.
Bang YJ
Arch Pathol Lab Med; 2012 Oct; 136(10):1201-4. PubMed ID: 23020724
[TBL] [Abstract][Full Text] [Related]
43. Treatment of elderly patients or patients who are performance status 2 (PS2) with advanced Non-Small Cell Lung Cancer without epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) translocations - Still a daily challenge.
Su C; Zhou F; Shen J; Zhao J; O'Brien M
Eur J Cancer; 2017 Sep; 83():266-278. PubMed ID: 28763691
[TBL] [Abstract][Full Text] [Related]
44. Novel drugs against non-small-cell lung cancer.
Pirker R
Curr Opin Oncol; 2014 Mar; 26(2):145-51. PubMed ID: 24406751
[TBL] [Abstract][Full Text] [Related]
45. Targeted Therapy for NSCLC--A Double-edged Sword?
Dempke WC
Anticancer Res; 2015 May; 35(5):2503-12. PubMed ID: 25964523
[TBL] [Abstract][Full Text] [Related]
46. Role of chemotherapy and targeted therapy in early-stage non-small cell lung cancer.
Nagasaka M; Gadgeel SM
Expert Rev Anticancer Ther; 2018 Jan; 18(1):63-70. PubMed ID: 29168933
[TBL] [Abstract][Full Text] [Related]
47. ALK inhibitors, resistance development, clinical trials.
Rothenstein JM; Chooback N
Curr Oncol; 2018 Jun; 25(Suppl 1):S59-S67. PubMed ID: 29910648
[TBL] [Abstract][Full Text] [Related]
48. Adjuvant therapy for nonsmall cell lung cancer: recent advances and future perspectives.
Pakkala S; Ramalingam SS
Curr Opin Oncol; 2016 Mar; 28(2):150-8. PubMed ID: 26809014
[TBL] [Abstract][Full Text] [Related]
49. Personalized therapy for non-small cell lung cancer: which drug for which patient?
Villaruz LC; Socinski MA
Semin Thorac Cardiovasc Surg; 2011; 23(4):281-90. PubMed ID: 22443647
[TBL] [Abstract][Full Text] [Related]
50. Targeted Therapy for Patients With Metastatic Non-Small Cell Lung Cancer.
Reckamp KL
J Natl Compr Canc Netw; 2018 May; 16(5S):601-604. PubMed ID: 29784736
[TBL] [Abstract][Full Text] [Related]
51. Rates of Guideline-Concordant Surgery and Adjuvant Chemotherapy Among Patients With Early-Stage Lung Cancer in the US ALCHEMIST Study (Alliance A151216).
Kehl KL; Zahrieh D; Yang P; Hillman SL; Tan AD; Sands JM; Oxnard GR; Gillaspie EA; Wigle D; Malik S; Stinchcombe TE; Ramalingam SS; Kelly K; Govindan R; Mandrekar SJ; Osarogiagbon RU; Kozono D
JAMA Oncol; 2022 May; 8(5):717-728. PubMed ID: 35297944
[TBL] [Abstract][Full Text] [Related]
52. [Current knowledge on perioperative treatments of non-small cell lung carcinomas].
Brosseau S; Naltet C; Nguenang M; Gounant V; Mordant P; Milleron B; Castier Y; Zalcman G
Rev Mal Respir; 2017 Jun; 34(6):618-634. PubMed ID: 28709816
[TBL] [Abstract][Full Text] [Related]
53. Targeted therapy moves to earlier stages of non-small-cell lung cancer: emerging evidence, controversies and future challenges.
Mielgo-Rubio X; Martín M; Remon J; Higuera O; Calvo V; Jarabo JR; Conde E; Luna J; Provencio M; De Castro J; López-Ríos F; Hernando-Trancho F; Couñago F
Future Oncol; 2021 Oct; 17(30):4011-4025. PubMed ID: 34337973
[TBL] [Abstract][Full Text] [Related]
54. Targeted therapy with anaplastic lymphoma kinase inhibitors in non-small cell lung cancer even with brain metastasis.
Muhammet Hacioglu B; Kostek O; Erdogan B; Uzunoglu S; Cicin I
J BUON; 2017; 22(3):586-591. PubMed ID: 28730760
[TBL] [Abstract][Full Text] [Related]
55. Integration of immunotherapy into adjuvant therapy for resected non-small-cell lung cancer: ALCHEMIST chemo-IO (ACCIO).
Sands JM; Mandrekar SJ; Kozono D; Oxnard GR; Hillman SL; Wigle DA; Govindan R; Carlisle J; Gray J; Salama JK; Raez L; Ganti A; Foster N; Malik S; Bradley J; Kelly K; Ramalingam SS; Stinchcombe TE
Immunotherapy; 2021 Jun; 13(9):727-734. PubMed ID: 33878954
[TBL] [Abstract][Full Text] [Related]
56. Targeted Therapies in Early Stage NSCLC: Hype or Hope?
Friedlaender A; Addeo A; Russo A; Gregorc V; Cortinovis D; Rolfo CD
Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32878298
[TBL] [Abstract][Full Text] [Related]
57. NGS analysis on tumor tissue and cfDNA for genotype-directed therapy in metastatic NSCLC patients. Between hope and hype?
Falk AT; Heeke S; Hofman V; Lespinet V; Ribeyre C; Bordone O; Poudenx M; Otto J; Garnier G; Castelnau O; Guigay J; Leroy S; Marquette CH; Hofman P; Ilié M
Expert Rev Anticancer Ther; 2017 Aug; 17(8):681-685. PubMed ID: 28511612
[TBL] [Abstract][Full Text] [Related]
58. Emerging targeted therapies in non-small cell lung cancer.
Khanal N; Ganti AK
Expert Rev Anticancer Ther; 2016; 16(2):177-87. PubMed ID: 26618563
[TBL] [Abstract][Full Text] [Related]
59. Current status of targeted therapy in non-small cell lung cancer.
Parums DV
Drugs Today (Barc); 2014 Jul; 50(7):503-25. PubMed ID: 25101332
[TBL] [Abstract][Full Text] [Related]
60. Adjuvant therapy in non-small cell lung cancer: is targeted therapy joining the standard of care?
Gabay C; Russo A; Raez LE; Rolfo Cervetto C
Expert Rev Anticancer Ther; 2021 Nov; 21(11):1229-1235. PubMed ID: 34528869
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
